NEJM PUBLISHES STUDIES OF VELCADE FOR INJECTION

Millennium Pharmaceuticals has announced the publication of results from two clinical trials in this week's The New England Journal of Medicine.

The first publication reports results from the Phase III APEX study which showed Velcade was superior in survival, time to disease progression, and response rates compared to standard of care, high-dose dexamethasone, in patients with relapsed multiple myeloma.

Results from a second study, published in the same issue, detail findings from a randomized Phase II trial of the investigational drug MLN02 in patients with ulcerative colitis that demonstrated statistically significant improvements in remission rates in patients compared to placebo, the trial's primary endpoint.